Technology | Vascular Access | September 03, 2019

Adept Medical Launches Antegrade IR Platform

Platform provides work surface for antegrade femoral approach during vascular interventional procedures

Adept Medical Launches Antegrade IR Platform

September 3, 2019 — New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven, it is placed to provide an ideal work surface for antegrade femoral approach during interventional radiology vascular procedures. The device sits within the company’s existing range of access and patient positioning devices designed for interventional radiology, cardiology and vascular procedures.

Designed to provide a stable, radiolucent, height- and length-appropriate work surface for supporting lightweight equipment during the antegrade femoral approach, the Antegrade IR Platform offers clinical benefits to the current practice of laying procedural equipment on the mattress and patient. 

The narrow portion of the Antegrade IR Platform extends alongside the patient towards the femoral artery, offering a steady platform for the clinician to rest their wrists on during wire manipulation. It can be set up at two different lengths and various heights according to the patient and procedure, providing flexibility. 

Ideally used in conjunction with the Adept Medical Drape Support (AM1000) and ArmSure (AM0600), these two products offer drape management, patient comfort and security during interventional radiology procedures. 

Crafted from carbon fiber composite and high-performance engineering plastics, the Antegrade IR Platform is lightweight yet strong, and has a high resistance to chemical attack from commonly used cleaning products. 

For more information: www.adeptmedical.co.nz

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...